ConductScience.org, home

Gene · 9733

SART3: spliceosome associated factor 3, U4/U6 recycling protein

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. SART3: spliceosome associated factor 3, U4/U6 recycling protein. Genes, record 9733. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9733

On this page

Gene

Symbol
SART3
HGNC
Name
spliceosome associated factor 3, U4/U6 recycling protein
HGNC
NCBI Gene ID
9733
NCBI Gene
HGNC ID
HGNC:16860
HGNC
Ensembl
ENSG00000075856
NCBI Gene
Aliases
DSAP1, KIAA0156, P100, RP11-13G14, TIP110, p110, p110(nrb)
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q15020Spliceosome associated factor 3, U4/U6 recycling protein9639Ensembl, GeneID, HGNC

Source UniProt

Patents61

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1465385Q15020Espacenet
EP 4650780 A22025-11-1916603Q15020Espacenet
EP 4641201 A22025-10-2920486Q15020Espacenet
JP 2025517969 A2025-06-1220486Q15020Espacenet
JP 2025517970 A2025-06-1216603Q15020Espacenet
EP 4487869 A22025-01-08438Q15020Espacenet
JP 2024509935 A2024-03-051157Q15020Espacenet
KR 1020240027895 A2024-03-04626Q15020Espacenet
JP 2023036863 A2023-03-14626Q15020Espacenet
US 11446398 B22022-09-2083785Q15020Espacenet

1 to 10 of 61

See all 61 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,075

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleSART3 papersNewest fiscal year
P30CA016672Cancer Center Support Grant122025
P30CA068485Cancer Center Support Grant62025
P30CA021765Cancer Center Support Grant (CCSG)52025
P30CA008748Cancer Center Support Grant42025
P30CA013330Cancer Center Support Grant42025
R01AG011085Ubiquitin‐mediated proteolysis and cell cycle control42025
P30AI027763UCSF-Bay Area Center for AIDS Research32025
P30CA006973Regional Oncology Research Center32025
P30CA060553The Robert H. Lurie Comprehensive Cancer Center32025
P30CA091842Cancer Center Support Grant32025

1 to 10 of 1,075Source NIH's project files

See all 1,075 nih grants

Papers1,339

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance.iScience202642221825PubTator, text miningPubMed
A bioinformatics pipeline for the design of a SART3-targeted cancer vaccine with enhanced immunogenicity.Genomics Inform202642067955PubTator, text miningPubMed
LncRNA LASTR promotes TGF-β signalling and EMT in HNSCC by enhancing TGFβR1 expression by suppressing biogenesis of miR-34a and acting as its ceRNA.Cell Signal202641812719PubTator, text miningPubMed
Rabies lyssavirus phosphoprotein possesses RNA duplex-unwinding activities.Mol Ther Nucleic Acids202641783789PubTator, text miningPubMed
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening.Sci Rep202641775739PubTator, text miningPubMed
TIE2-positive cells in the nucleus pulposus with a purpose: the who, what and why.J Biomed Sci202641772594PubTator, text miningPubMed
Research Progress on the Biological Function, Disease-Driving Mechanism and Clinical Targeting Strategies of G3BP2.Molecules202641752399PubTator, text miningPubMed
Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes.Int J Mol Sci202641752040PubTator, text miningPubMed
Identification of two novel MVD mutations and one novel FDPS mutation in Chinese patients with porokeratosis.Front Med (Lausanne)202641737384PubTator, text miningPubMed
Advances in T cell-based immunotherapy for osteosarcoma.Front Immunol202641727478PubTator, text miningPubMed

1 to 10 of 1,339

See all 1,339 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/9733

GET https://conductscience.org/api/genes/v1/9733/patents?page=2